Z

Zeiss

Manufactures high-precision optical instruments and devices

Quality Manager - Consumer Health Products

Full-Time
$119.7k - $149.6k/yr
Senior
Bachelor's
Princeton, NJ, USA+1 moreMore locations: Hebron, KY, USA
In Person
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • 5+ years of experience in Quality Assurance, Quality Systems, Supplier Quality, Regulatory Affairs, or Compliance within an FDA-regulated industry.
  • Direct experience in one or more of the following areas: over-the-counter drugs, pharmaceuticals, sterile products, medical devices, dietary supplements, cosmetics, personal care, or regulated consumer health products.
  • Strong working knowledge of good manufacturing practice quality systems, including deviations, corrective and preventive action, change control, document control, complaints, supplier quality, training, and audit readiness.
  • Experience working with external partners such as third-party logistics providers, distributors, warehouses, laboratories, or outsourced manufacturers.
  • Ability to review technical quality documentation, identify risks and gaps, and drive required follow-up.
  • Strong written and verbal communication skills with the ability to translate regulatory and quality expectations into clear procedures, training, and business processes.
Responsibilities
  • Provide direct quality oversight of local warehousing, third-party logistics partners, distribution processes, transit temperature monitoring, and controlled room temperature storage programs.
  • Ensure quality expectations are clearly defined, documented, and executed across warehousing and distribution operations.
  • Manage local quality activities related to product hold, release, rejection, escalation, and recall readiness.
  • Partner with Operations and external logistics partners to identify quality risks, resolve issues, and drive continuous improvement.
  • Maintain inspection-ready Quality Management Systems for assigned regulated products and distribution activities.
  • Manage document control, change control, deviations, corrective and preventive action, complaints, training, supplier quality, and recall readiness processes.
  • Help maintain compliance with 21 CFR 210/211, 21 CFR 111, cosmetic quality expectations, MoCRA-related requirements, and internal quality standards.
  • Author, revise, and implement Standard Operating Procedures, work instructions, forms, and training materials.
  • Lead site readiness for FDA, customer, supplier, and internal audit activities.
  • Track quality metrics, identify trends, and drive continuous improvement.
  • Review quality documentation including batch records, Certificates of Analysis, Certificates of Conformance, deviation summaries, sterility assurance records, environmental monitoring summaries, media fill summaries, and corrective and preventive action responses, where applicable.
  • Support product disposition activities by ensuring required documentation is complete, accurate, and aligned with specifications and quality agreements.
  • Work with Supplier Quality, Regulatory Affairs, Operations, and external manufacturers to maintain effective contract manufacturing organization and supplier oversight.
  • Support supplier qualification, audit readiness, audit follow-up, quality agreements, and supplier corrective and preventive action tracking.
  • Resolve documentation gaps, deviations, supplier quality issues, and product quality questions through timely cross-functional follow-up.
  • Manage product quality complaint triage, investigation, documentation, trending, and closure.
  • Serve as a Tier 2 Quality escalation partner for Customer Service, Regulatory Affairs, Operations, and other internal teams.
  • Help distinguish product quality complaints from potential adverse events or medical inquiry escalations.
  • Coordinate adverse event escalation activities with Regulatory Affairs, Customer Service, designated reporting partners, and external safety resources.
  • Ensure timely documentation, communication, and follow-up for complaint and safety-related escalations.
  • Identify recurring complaint trends and potential quality signals requiring further investigation or escalation.
  • Support quality review of product labeling, packaging, and product documentation for over-the-counter drugs, dietary supplements, cosmetics, and related consumer health products.
  • Partner with Regulatory Affairs on Drug Facts, Supplement Facts, cosmetic labeling, claims review, MoCRA-related documentation, product listings, registrations, and related regulatory activities.
  • Stay current on relevant FDA regulations, guidance, and industry expectations impacting over-the-counter drugs, dietary supplements, cosmetics, and consumer health products.
Desired Qualifications
  • Direct experience with over-the-counter drug products, sterile ophthalmic products, controlled room temperature distribution, temperature monitoring, or cold-chain distribution models.
  • Familiarity with 21 CFR 210/211, 21 CFR 111, MoCRA, ISO 22716, or related distribution quality and stability standards.
  • Experience supporting product quality complaint investigations and coordinating adverse event escalation processes with Regulatory Affairs or external reporting partners.
  • Experience with contract manufacturing organization oversight, quality agreements, supplier audits, and supplier corrective and preventive action.
  • Experience reviewing sterility assurance records, environmental monitoring summaries, media fill summaries, or aseptic processing documentation.
  • ASQ Certified Quality Auditor, ASQ Certified Manager of Quality/Organizational Excellence, Regulatory Affairs Certification, or a related professional certification.
  • Regulatory Affairs Certification or training.
  • Certified Quality Auditor by ASQ.
  • Certified Manager of Quality/Organizational Excellence.

About the company

ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-half 2025/26 revenue reached €5.841 billion, with EBIT rising to €955 million.
  • ZEISS CLINIC 360 won FDA 510(k) clearance on August 19, 2026.
  • EURETINA 2026 launches expanded retina imaging, cataract systems, and DORC brand integration.

What critics are saying

  • ZEISS Meditec plans up to 1,000 cuts by 2029, signaling margin pressure.
  • Göttingen workers entered mediation in February 2026 after Zeiss targeted roughly 140 jobs.
  • ASML scanner timing controls ZEISS SMT revenue; any slip delays optics demand immediately.

What makes Zeiss unique

  • ZEISS supplies ASML's exclusive EUV optics, anchoring High-NA lithography through 2030.
  • ZEISS Medical Technology bundles imaging, software, and surgery across one ophthalmic workflow stack.
  • ZEISS CLINIC 360 and Collaborative Care tie devices, cloud analytics, and referrals together.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↑ 4%

1 year growth

↑ 4%

2 year growth

↑ 4%
PR Newswire
Sep 24th, 2026
ZEISS unveils retinal imaging and surgical innovations at EURETINA 2026

ZEISS Medical Technology has announced expansions to its ZEISS Retina Workflow at the EURETINA 2026 congress in Vienna. The company introduced the ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device for streamlined retinal diagnostics. ZEISS also unveiled the HMDmd CR3, a head-mounted 3D display that connects with the ZEISS ARTEVO 850 surgical microscope. The company reported that its DORC ILM-BLUE and DORC MEMBRANEBLUE-DUAL vitreoretinal surgical dyes reached a 3 million milestone. Additionally, ZEISS announced that the DORC brand will be consolidated under the ZEISS brand name, unifying the company's ophthalmic offerings. The DORC TDC VELOCE cutter continues to show improvements in 27G vitrectomy procedures, with clinical data suggesting up to 41% shorter core vitrectomy times.

PR Newswire
Sep 17th, 2026
ZEISS expands retinal imaging portfolio with new ALTA DUO 300 multimodal OCT device

ZEISS Medical Technology has expanded its retinal imaging portfolio with the launch of ZEISS ALTA DUO 300, a fully automated, compact multimodal imaging solution. The device combines optical coherence tomography (OCT) and fundus photography in a single unit, designed to provide efficient retinal assessment for eye care practices. The ALTA DUO 300 features four key diagnostic technologies: automated structural OCT with reference database and reporting, true colour fundus camera, AI-enhanced OCT-Angiography, and full chamber depth anterior OCT scanning. The device aims to integrate retinal imaging into everyday patient care through simplified workflows. The product will be showcased at the European Society of Retina Specialists congress in Vienna from 1-4 October and will be available in select markets later in 2026.

Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.

ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.